Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02620787 · ClinicalTrials.gov registry record · Phase 1
Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis
A Phase 1 study, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02620787 is a Phase 1 study that has completed, run by Hartford Hospital. The registered enrollment target is 18 participants.
The verdict
NCT02620787, a Phase 1 study, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study will determine the tissue penetration of tedizolid (Sivextro, Merck \& Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer control participants.
Interventions
- PROCEDURE Microdialysis Catheter Insertion
- DRUG Tedizolid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-02-23 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02620787
The ClinicalTrials.gov registry entry for NCT02620787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Microdialysis Catheter Insertion is the first listed.
NCT02620787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02620787 about?
NCT02620787 is a clinical study titled "Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis". This study will determine the tissue penetration of tedizolid (Sivextro, Merck \& Co.), a novel oxazolidinone antibiotic, into the extracellular, interstitial fluid of soft tissue in diabetic patients with lower limb wound infections. Penetration will be compared with a group of healthy volunteer co...
What is the current status of trial NCT02620787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2016-02-23. Estimated completion is 2017-03-01.
What interventions are being tested in trial NCT02620787?
The interventions under investigation include: Microdialysis Catheter Insertion (PROCEDURE), Tedizolid (DRUG).
Who is sponsoring clinical trial NCT02620787?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.